Cargando…
Prospective evaluation of long-term safety of dual-release hydrocortisone replacement administered once daily in patients with adrenal insufficiency
OBJECTIVE: The objective was to assess the long-term safety profile of dual-release hydrocortisone (DR-HC) in patients with adrenal insufficiency (AI). DESIGN: Randomised, open-label, crossover trial of DR-HC or thrice-daily hydrocortisone for 3 months each (stage 1) followed by two consecutive, pro...
Autores principales: | Nilsson, A G, Marelli, C, Fitts, D, Bergthorsdottir, R, Burman, P, Dahlqvist, P, Ekman, B, Edén Engström, B, Olsson, T, Ragnarsson, O, Ryberg, M, Wahlberg, J, Lennernäs, H, Skrtic, S, Johannsson, G |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Bioscientifica Ltd
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4106399/ https://www.ncbi.nlm.nih.gov/pubmed/24944332 http://dx.doi.org/10.1530/EJE-14-0327 |
Ejemplares similares
-
Long-term safety of once-daily, dual-release hydrocortisone in patients with adrenal insufficiency: a phase 3b, open-label, extension study
por: Nilsson, Anna G, et al.
Publicado: (2017) -
Improved Urinary Cortisol Metabolome in Addison Disease: A Prospective Trial of Dual-Release Hydrocortisone
por: Espiard, Stéphanie, et al.
Publicado: (2020) -
Achieving a physiological cortisol profile with once-daily dual-release hydrocortisone: a pharmacokinetic study
por: Johannsson, Gudmundur, et al.
Publicado: (2016) -
Metabolic Effects of Cortisone Acetate vs Hydrocortisone in Patients With Secondary Adrenal Insufficiency
por: Ekstrand, Elise, et al.
Publicado: (2020) -
OR30-06 Hospitalisation, Intensive Care And Death Due To COVID-19 In Swedish Patients With Adrenal Insufficiency
por: Bergthorsdottir, Ragnhildur, et al.
Publicado: (2023)